02.09.21

World Sepsis Pipeline Insight 2021: Pipeline Product Profiles, Therapeutic Assessment, Pipeline Assessment, Inactive Drugs Assessment, Unmet Needs – ResearchAndMarkets.com

Yahoo!Finance

Excerpt

·4 min read

The “Sepsis Pipeline Insight 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This “Sepsis – Pipeline Insight, 2021,” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Sepsis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The companies and academics are working to assess challenges and seek opportunities that could influence Sepsis R&D. The therapies under development are focused on novel approaches to treat/improve Sepsis.

Sepsis Emerging Drugs Chapters

This segment of the Sepsis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sepsis Emerging Drugs

VBI-S: Vivacelle Bio

VBI-S is made of small particles of specific lipid called micelles and liposomes for the treatment of hypotension. VBI-S is an intravenously injectable fluid comprised of phospholipid nanoparticles that were specifically designed to shift the biophysical properties of the body’s fluid volume in hypovolemic shock, due to sepsis, from non-survival to survival. The therapy is currently under phase II clinical evaluation for the treatment of hypovolemia due to sepsis/septic shock.

Read the full story here.

X
×

Enter search term...

close ×

REIMAGINE: Survive and Thrive During COVID-19

Browse our new digital guide for strategies and resources

Read Now